SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

DelveInsight’s, “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ ...

AbbVie made a $350 million upfront payment to Gubra for rights to the drug, called GUB014295. Gubra is also eligible to receive another $1.9 billion if certain development and sales milestones are met ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

Barclays analyst Peter Lawson says SpringWorks Therapeutics (SWTX) this morning cancelled from the firm’s conference next week, following ...

Ahead of Merck KGaA’s earnings announcement Thursday, investors were mostly looking forward to any comments about its ...

Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a biopharma company making medicines for people with severe rare diseases and ...

SpringWorks Therapeutics Inc . (NASDAQ ... most significant developments for SpringWorks is the ongoing merger and acquisition discussions with Merck KGaA. Analysts view this potential acquisition as ...